In other solid tumors (e.g., esophageal, stomach, gynecological, pancreas, head and neck squamous cell carcinoma), the sometimes-notable CRP increase can indicate poor survival or the presence of metastases, determine treatment outcomes or tumor recurrence, and advanced stages, and correlates well with tumor size and disease progression. Here, CRP is linked to neoplasm.